Joint Formulary & PAD

Lutein and antioxidants - Prevention of age-related macular degeneration

You are here : Home > Formulary Search > Lutein and antioxidants - Prevention of age-related macular degeneration

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Non Formulary
Formulations :
  • Not Specified
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
SPC
Restrictions / Comments :
Important

Listed in 'Items which should not routinely be prescribed in primary care: policy guidance'. Click drug name for details and exceptions.

 

Status 2

See narrative
Formulations :
  • Not Specified
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
SPC
Restrictions / Comments :

Documentation

Guidelines (National)
NHS England Items which should not routinely be prescribed in primary care: policy guidance - August 2025
Patient resource
Lutein and antioxidants - Patient Information - NHS England do not prescribe - Jan-18

PAD Profile

ChemicalSubstance :
Lutein and antioxidants
Indication :
Prevention of age-related macular degeneration
Group Name :
Keywords :
Lutein, Zeaxanthin, eye-only, eye only, supplement, Vitamin C, Vitamin E, Zinc, Copper, ophthalmology, Vitamin and mineral food supplement, ocular health, ocular, wet AMD, low value medicines, drugs of low clinical value, LVM, drugs of limited clinical value
Brand Names Include :
MacuLEH, Occuvite complete capsule, Preservision original, Viteyes original, Preservision Lutein capsules, Formula Plus Lutein, Icaps, Visionace Plus, Visionace original
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
2
Traffic Light Entries :
2

Committee Recommendations (2)

03 Jun 20 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

At the Surrey and North-West Sussex Area Prescribing Committee (APC) held in June 2020, it was decided that all BLACK status drugs would have their review dates extended for 5 years without the need for a review.

If a clinician or provider wishes to change the traffic light status of any BLACK drug then they will need to submit a paper for change as per usual APC process.

22 Jan 18 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The Prescribing Clinical Network does not recommend the prescribing of lutein and antioxidants for the prevention of age related macular degeneration and they will be given a BLACK status on the traffic light system for this indication.
Patients who are recommended to take these supplements can purchase these products over the counter from pharmacies.
Prescribers should:
- NOT initiate lutein and antioxidants in any new patient
AND
- De-prescribe lutein and antioxidants in current patients, in line with NHS England guidance.

Other Indications

Below are listed other indications that Lutein and antioxidants is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Prevention of age-related macular degeneration.

  • No records returned.